Harvesting Cells for Experimental Cancer Treatments

StatusEnrolling by Invitation
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 503 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. New version filed on ClinicalTrials.gov
  4. 47 versions Re-verified since Oct 23, 2024, no change to tracked fieldsv454-v500
5,486 trials monitored
See 312 trials at risk
4,822 trials monitored
See 269 trials at risk
and 1 more disease
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers.
Trial Details
NCT Number NCT00068003
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms
Enrollment 7,000 participants
Start Date
Updated on ClinicalTrials.gov